SPC
KLRS

Sigma Planning Corp’s Kalaris Therapeutics KLRS Stock Holding History

Sigma Planning Corp’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.4K Buy
+10,167
New +$52.8K ﹤0.01% 1398

Other funds holding KLRS

WT
WHI Trust Chicago, Illinois $155M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
FCA
Fortis Capital Advisors Prairie Village, Kansas $889M AUM 36.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WAM
WealthTrust Asset Management Destin, Florida $185M AUM 26.82% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SFCL
Strengthening Families & Communities LLC Boston, Massachusetts $450M AUM 41.19% 1-Year Est. Return

Sigma Planning Corp's KLRS Position: Q2 2026 in Review

Sigma Planning Corp opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 10,167 shares worth $41.4K. The stake represents ﹤0.01% of the portfolio and ranks #1398 among its holdings.

14 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Sigma Planning Corp held 10,167 shares of Kalaris Therapeutics worth $41.4K as of Q2 2026.
  • Kalaris Therapeutics was a new Sigma Planning Corp position in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Sigma Planning Corp's portfolio in Q2 2026, its #1398 holding.
  • 14 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.